Gimsilumab for COVID-19: real-time analysis

Download Image

Post

c19early.org

Gimsilumab for COVID-19

1 study with 225 patients

Serious outcome risk

Gimsilumab

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Gimsilumab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−10%

Mortality (1)−10%

RCTs (1)−10%

Late (1)−10%

00.511.5+

← Gimsilumab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jun 1 2022	Criner et al., American Journal of Respiratory and Critical Care Medicine, doi:10.1164/rccm.202108-1859OC	Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial
Jun 1 2022	10% higher mortality (p=0.71). RCT 225 hospitalized COVID-19 patients showing no significant difference in mortality or clinical outcomes with the anti-GM-CSF monoclonal antibody gimsilumab compared to placebo.